Thousands of bottles of atorvastatin, the generic version of Lipitor and the best-selling drug in the US, have been recalled due to a manufacturing defect that could reduce the medication's effectiveness. The recall, initially issued by Ascend Laboratories on 19 September 2025, affects approximately 142,000 bottles of the cholesterol-lowering drug.
The US Food and Drug Administration (FDA) classified the recall as Class II on 10 October, meaning the medication could cause temporary or medically reversible adverse health consequences. The defect was identified during routine quality testing, where sample pills failed to dissolve properly. This issue affected batches manufactured from November 2024 through September 2025.
If the tablets do not dissolve correctly, the amount of active ingredient absorbed by the body is substantially reduced. Lowering LDL cholesterol with atorvastatin has been shown to reduce cardiovascular events such as heart attacks and strokes by 22% over several years. A 2021 study found that stopping statin use for six months increased the risk of cardiovascular events, deaths, and emergency room visits by 12% to 15%.
Patients are advised not to stop taking their medication without consulting a pharmacist or prescriber, as taking the recalled pills is still better than taking none. To check if their medication is affected, patients should look for 'MFG Ascend' or 'MFR Ascend' on the prescription label, or the National Drug Code (NDC) starting with 67877. Pharmacists can cross-reference the lot number with the FDA's recall list.
The defective atorvastatin is manufactured by Alkem Laboratories in India, highlighting ongoing concerns about the FDA's ability to oversee overseas pharmaceutical production. This recall is the latest in a series of manufacturing issues since 2019, raising questions about drug quality and regulatory oversight.
